In an attempt to boost its pipeline, Roche has agreed to acquire Telavant Holdings from Roivant Sciences and Pfizer in a deal worth up to US$7.25 B. Through the agreement, Roche will gain rights to develop, manufacture and commercialise Phase III-ready TL1A-directed antibody, RVT-310, in the US and Japan for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. The deal comes at a particularly busy time for TL1A therapies as other big pharma companies, such as Merck & Co. and Sanofi, have similarly announced big ticket deals within the space.